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ABSTRACT
The role of Gas6 in endothelial cell (EC) function remains incompletely characterized.
Here, we report that Gas6 amplifies EC activation in response to inflammatory stimuli in
vitro. In vivo, Gas6 promotes and accelerates the sequestration of circulating platelets and
leukocytes on activated endothelium as well as the formation and endothelial
sequestration of circulating platelet-leukocyte conjugates. In addition, Gas6 promotes
leukocyte extravasation, inflammation and thrombosis in mouse models of inflammation
(endotoxinemia, vasculitis, heart transplantation). Thus, Gas6 amplifies EC activation,
thereby playing a key role in enhancing the interactions between ECs, platelets and
leukocytes during inflammation.
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INTRODUCTION
The growth arrest-specific gene 6 (Gas6) binds to the receptor tyrosine kinases Axl,
Tyro3 and Mer 1. Gas6 is composed of a N-terminal gamma-carboxy-glutamic acid domain
(Gla-domain), a loop region, four EGF-like repeats, and a C-terminal steroid hormone
binding globulin-like (SHBG-like) domain) 1. Even though this molecule was discovered as
a homologue of the anti-coagulant Protein S more than a decade ago, its role in vivo
remains incompletely characterized 2,3. Originally identified in fibroblasts, Gas6 is
expressed in various cell types, including endothelial cells (ECs) 4, smooth muscle 5, and
bone marrow cells 6. Gas6 and its receptors modify platelet activation and aggregation 7-10,
but the role of Gas6 in the interplay between platelets and other cell types, such as ECs
and leukocytes 11, during inflammatory conditions remains unclear.
Several lines of evidence indeed suggest that Gas6 may affect ECs and leukocytes.
ECs and leukocytes express Gas6 and its receptors, especially in conditions of
inflammation and repair 4,12-16. Gas6 stimulates EC survival 17-20 and promotes
angiogenesis by enforcing the adhesion of Axl-expressing ECs via homophilic interactions
21-23, yet another study suggested that activation of Axl impairs tyrosine phosphorylation of
VEGF receptor-2 24. The activity of Gas6 on leukocytes also remains incompletely
understood. Indeed, genetic loss of Mer inhibits cytokine production by natural killer cells
25, while it stimulates TNFa production by monocytes 14 and impairs clearance of apoptotic
cells 26. Loss of all three Gas6 receptors, on the other hand, induces lymphoproliferative
disorders via hyperactivation of antigen-presenting cells 27,28, but mice lacking Gas6
(Gas6-/-) do not develop auto-immune health problems (unpublished). In humans, the
plasma levels of Gas6 were found to be elevated during severe sepsis – a life-threatening
condition involving increased interactions between ECs, leukocytes and platelets 29,30.
However, exogenous Gas6 inhibits granulocyte adhesion to ECs, but only at very high
doses 31. Furthermore, the role of endogenous Gas6 in leukocyte extravasation in vivo
was not studied. Here, by using our previously generated Gas6-/- mice 7, we studied
whether Gas6 might play a role in EC activation and in the interactions between ECs,
platelets and leukocytes during inflammatory conditions.
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EXPERIMENTAL METHODS
Mice
The generation of Gas6-/- mice has been described 7. The original line was back-crossed
into a C57BL/6 background for more than 10 generations, yielding congenic C57BL/6
Gas6-/- mice.  Housing and all experimental animal procedures were approved by the
Institutional Animal Care and Research Advisory Committee of the K.U. Leuven.
ELISA for mGas6
An ELISA for murine Gas6 was developed using commercially available antibodies and
standard  (R&D Systems).
In vitro endothelial cell activation assays
Primary mouse ECs were isolated from matrigel granulomas 32. Production of Gas6 was
determined after culturing 1 x 105 cells for 24h in low serum containing culture medium.
Expression of adhesion molecules and cytokines was determined as described 33. In brief,
ECs were plated at 2000 cells/well in 96-well tissue culture plates and grown at 37ºC in
5% CO2 for 24 hrs. At the time of the experiment, culture medium was removed and
replaced by serum-free medium containing vehicle or recombinant mouse (rm)TNFa (100
ng/ml; R&D Systems). After 24 hours, cells were washed once with serum-free medium.
Specific antibodies for mICAM-1 and mVCAM-1 (R&D Systems) were added to each well
and incubated at 37 ºC in 5% CO2 for 1 to 2 hours. After incubation with a horseradish
peroxidase-conjugated secondary antibody the HRP activity was determined. The data
represent the mean ± SEM of triplicates obtained from three different experiments. Levels
of IL-6 and IL-1ß in the culture medium were measured using commercially available
ELISAs (R&D Systems). HUVECs were cultured in EGM medium (Cambrex)
supplemented with hEGF and hydrocortisone. Fresh Heparine and ECGS (HE) were
added at each passage. For electroporation with Gas6, Axl, Tyro3 or control siRNA
(Qiagen), 90% confluent HUVECs were nucleofected using the Nucleofector device
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(Amaxa Gmbh) according to the manufacturer’s instruction (nucleofector program A-034).
At 24 hours after nucleofection, HUVECs were stimulated for 24 hours with rhTNF-a (R&D
Systems) in medium without HE. Cell lysates were analyzed for hICAM-1 expression using
a commercially available ELISA (R&D Systems).
In vivo study of platelet tethering, rolling and adhesion
Videomicroscopy on mesenteric venules was performed as described with slight
modifications 34. Briefly, recipient C57Bl6 WT or Gas6-/- mice were anesthetized with
urethane (1.4 mg/kg) to maintain physiological blood pressure and heart rate, and the
external jugular vein was cannulated for continuous venous access. Non-activated
platelets of donor syngeneic WT or Gas6-/- mice (1 donor per 1 recipient mouse) were
fluorescent-labeled with calcein, and slowly infused via the catheter. Alternatively,
rhodamine 6G (1 mg/ml in saline) was infused to label circulating cells in vivo; platelets
and leukocytes were clearly distinguishable by size. Gallic acid (GA; 3.4 mg/kg/h),
previously shown to selectively inhibit P-selectin, was continuously administered
intravenously via an infusion pump, as described previously 34,35. The mesentery of
recipient mice was externalized and mesenteric venules were exposed on the table of an
epifluorescence microscope for direct visualization under videomicroscopy. Local EC
activation was induced via topical application of the calcium ionophore A23187 (10 µl at 30
µM). Platelet activation was induced by i.v. bolus injection of collagen (50 µg/kg),
combined with a a IIbb3 antagonist (G4120, 1 mg/kg) to prevent platelet aggregation.
Movies were recorded 10 min after activation at 10 frames per sec, and analyzed post-hoc
using NIH image 1.62 software. For kinetic analysis, movies with a duration of 1 min were
recorded at indicated time points. The following criteria were used: cells were
tethering/rolling when a clear cell/stripe was present on 3 or more consecutive frames;
cells were adhering/arrested when a clear arrest of cells was present on 2 or more
consecutive frames; conjugates were interacting when a clearly more intense fluorescence
signal containing at least 2 separately identifiable platelets was present on 3 or more
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consecutive frames. Data were expressed as cells per min. The mean number of infused
platelets (± 50 x 106 in 200 µl) and the sizes of the analyzed mesenteric venules (120-150
µm diameter) were not different between genotypes. Determination of Weibel-Pallade
body count and FACs analysis are described in the supplemental methods.
In vivo model of endothelial cell activation
Mice were injected i.p. with a sublethal dose of recombinant mouse TNF-a (100 µg/kg;
R&D Systems), hearts were harvested after 24 hours and immediately embedded in
Tissue-Tek in liquid nitrogen-cooled 2-methylbutane. Seven µm sagittal sections were
briefly fixed in aceton and immunostained with a biotinylated rat anti-VCAM-1 (1:50, BD
Biosciences) or a rat anti-ICAM-1 antibody (CD54, 1:100, Seikagaku). Tissues were
stained by amplification with the tyramide signal amplification system (Perkin Elmer, Life
Sciences) using 3,3’-diaminobenzidine (DAB, Sigma) as a chromogen substrate and
counterstained with Harris hematoxilin.
Animal models
All animal models are described in the supplemental methods.
Statistical analysis
SPSS 11.0 was used for statistical analysis and P-values were calculated using unpaired
student’s t-tests, ANOVA or Fisher’s exact analyses. Data are represented as mean ±
SEM and were considered statistically significant at P<0.05.
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RESULTS
ENDOTHELIAL CELLS RELEASE GAS6
Gas6 is present in mouse blood plasma 36; recent reports suggest that endothelial
cells (ECs), which express Gas6 4, might be a potential source of plasma Gas6 29,37. By
ELISA, Gas6 was indeed detectable in plasma of wild type (WT) mice (29 ± 2 ng/ml) but
not in Gas6-/- mice. Gas6 was also detectable in murine platelets (28 ± 3 pg/106 platelets),
but undetectable in erythrocyte lysates. In baseline conditions (i.e., low serum without
supplementation of any inflammatory cytokine), cultured murine primary ECs constitutively
released Gas6 in the conditioned medium (708 ± 50 pg/106 cells/24h; N=5).
ENDOTHELIAL GAS6 PROMOTES ACTIVATION OF ENDOTHELIAL CELLS
To study the role of endothelial Gas6, we first investigated the response of cultured
ECs, derived from WT and Gas6-/- mice, to TNFa. After stimulating ECs for 24 hours with
100 ng/ml TNFa, we analyzed the endothelial expression of the activation markers VCAM-
1 and ICAM-1, and the release of the inflammatory cytokines IL-1ß and IL-6. In baseline
conditions (i.e. without TNFa), we found no genotypic differences in the expression of the
adhesion molecules (Figure 1A,B) or in the release of cytokines (ng per 106 cells per 24 h:
0.6 ± 0.1 for IL-1ß and 1 ± 0.1 for IL-6 in WT cells versus 0.5 ± 0.03 for IL-1ß and 0.8 ±
0.05 for IL-6 in Gas6-/- cells; P=NS). Upon TNFa stimulation, WT ECs expressed elevated
levels of VCAM-1 and ICAM-1 (Figure 1A,B), and released ~10-fold more IL-1ß and IL-6
(ng per 106 cells per 24 h: 6 ± 1 for IL-1ß and 11 ± 1 for IL-6; P<0.05 versus control). In
contrast, in the absence of Gas6, TNFa failed to activate ECs as evidenced by the lower
levels of adhesion molecules (Figure 1A,B) and cytokine release (ng per 106 cells per 24
h: 0.9 ± 0.1 for IL-1ß and 2 ± 1 for IL-6; P=NS versus control; P<0.05 versus WT). The
defective upregulation of VCAM-1 and ICAM-1 expression in Gas6-/- ECs was confirmed in
vivo. Indeed, by immunostaining, fewer ECs in the heart expressed VCAM-1 and ICAM-1
at 24h after a systemic challenge with TNFa in Gas6-/- than WT mice (Figure 1C-J). The
increased response of WT ECs to TNFa was, however, not due to (removed as requested)
an increased release of Gas6 by ECs, stimulated with TNFa (pg/106 cells/24h: 708 ± 50 in
baseline versus 669 ± 58 after TNFa; N=5; P=NS) (removed as requested).
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The effect of Gas6 was not restricted to murine ECs, but Gas6 also regulated the
activation of human ECs. Indeed, Gas6 was expressed in HUVECs (mRNA levels
normalized for transcript levels of TATA box binding protein, or TBP: 26.1 ± 0.3; N=3).
Knockdown with a Gas6-selective RNAi construct reduced the Gas6 expression in
HUVECs by -75% and reduced the expression of ICAM-1 in response to TNFa, while a
control plasmid (encoding a mismatched sequence) was ineffective (Figure 1K). Thus,
Gas6 promotes the responsiveness of ECs to an inflammatory stimulus.
AXL MEDIATES THE ENDOTHELIAL RESPONSE TO GAS6
      We also assessed which of the Gas6 receptors (Tyro-3, Axl, or Mer) on ECs
mediated the response to Gas6. All three receptors were expressed in HUVECs (mRNA
expression levels normalized to those of the TBP: 135 ± 3 for Axl, 13.4 ± 1.0 for Mer, and
3.2 ± 0.3 for Tyro3; N=3). Transfection of HUVECs with siRNAs for Axl or Tyro3 efficiently
reduced the expression of Axl and Tyro3 by ~70% and ~80%, respectively (mRNA levels
normalized to those of TBP: 45 ± 3 for Axl and 0.5 ± 0.1 for Tyro3; N=3). Knockdown of
these Gas6 receptors did not affect EC expression levels of ICAM-1 in baseline conditions.
However, the upregulation of ICAM-1 in response to TNFa was reduced upon knockdown
of Axl , but not of Tyro3 (Figure 1K). Unfortunately, knockdown of Mer failed to reduce the
expression of Mer in HUVECs (mRNA levels normalized to those of the TBP: 11.6 ± 1.4;
N=3), precluding further analysis. Thus, binding of Gas6 to Axl is dispensible for baseline
expression of ICAM-1, but necessary for the TNFa-induced expression of ICAM-1.
GAS6 PROMOTES THE SEQUESTRATION OF PLATELETS ONTO ENDOTHELIUM
Prompted by the finding that loss or knock-down of Gas6 in ECs impaired their
activation in response to inflammatory stimuli in vitro, we investigated the role of Gas6 in
EC activation in vivo. One of the predominant features of inflamed endothelium is the
enhanced interactions with circulating cells such as platelets and leukocytes, leading to
increased tethering, rolling, firm adhesion, extravasation and tissue infiltration of
leukocytes 11,38. To study the role of Gas6, we first determined, by intravital
videomicroscopy, the tethering, rolling and adhesion of calcein-labeled platelets onto
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mesenteric venules in WT and Gas6-/- mice 34,39. In baseline conditions, only a small
number of platelets sequestered onto ECs in either genotype (Figure 2A,B). To selectively
activate the endothelium, venules were locally superfused with the calcium ionophore
A23187. Significantly more platelets interacted with the activated endothelium in WT than
Gas6-/- mice (Figure 2A,B), indicating that ECs, activated in the absence of Gas6, failed to
efficiently sequester platelets.
We previously showed that Gas6-/- platelets exhibited impaired activation and
aggregation 7,10, but did not investigate whether they also interact less with the endothelial
surface. When selectively activating the platelets (by injecting collagen together with an
aIIbb3 antagonist to avoid aggregation), tethering, rolling and adhesion of platelets on ECs
in vivo was impaired in the absence of Gas6 (Figure 2A,B). Importantly, endothelial
sequestration of single platelets was also impaired in Gas6-/- mice when both platelets and
endothelium were activated (Figure 2A,B). Thus, Gas6 promotes the sequestration of
circulating platelets onto activated ECs in vivo.
GAS6 PROMOTES LEUKOCYTE SEQUESTRATION ON ENDOTHELIUM
To study the role of Gas6 in the sequestration of leukocytes on ECs, we also
determined, by intravital videomicroscopy, the interactions of circulating leukocytes with
the mesenteric endothelium, using another labeling protocol (in vivo labeling via rhodamin-
G infusion 40,41). Since leukocytes progressively sequester onto the activated endothelium
34, we analyzed both the number of sequestered leukocytes, as well as the kinetics of their
sequestration in response to A23187. In baseline conditions, only a small number of
leukocytes interacted with the mesenteric endothelium in either genotype (Figure 2C).
When the endothelium was selectively activated by topical A23187 administration,
leukocyte sequestration progressively increased in WT mice, reaching a plateau phase at
20 minutes after activation (Figure 2C ). In contrast, in Gas6-/- mice, leukocyte
sequestration was not only delayed but, in addition, significantly fewer leukocytes
interacted with the activated endothelium at all time points in the absence of Gas6 (Figure
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2C). Taken together, Gas6 amplifies and accelerates the sequestration of circulating
leukocytes onto activated ECs.
P-SELECTIN, A DOWNSTREAM MEDIATOR OF GAS6?
P-selectin promotes the rapid sequestration of leukocytes and platelets on ECs,
early after their activation 34,38,41-45. We therefore reasoned that the defective sequestration
of circulating cells on activated ECs in Gas6-/- mice might be attributable to an impaired
upregulation of P-selectin on these cells. In view of the lack of high-quality antibodies to
reliably and reproducibly detect P-selectin expression on endothelium, we resorted to a
functional characterization of the role of P-selectin in vivo. If the activity of Gas6 would
rely, at least in part, on upregulation of P-selectin, then P-selectin inhibitors would be
expected to reduce the sequestration of circulating cells on ECs in WT but not in Gas6-/-
mice. To neutralize P-selectin in vivo, we used gallic acid (GA), a well-known polyphenol
acting as a selective antagonist of P-selectin, but not of E-selectin 34,35,46. As expected
(since P-selectin is poorly expressed on quiescent ECs), GA did not alter the interactions
of leukocytes with resting endothelium in either genotype (Figure 2D). However, when the
endothelium was selectively activated by topical administration of A23187, GA inhibited
the interactions of leukocytes with ECs in WT mice, notably, to the same level as in Gas6-/-
mice, while GA was ineffective in Gas6-/- mice (Figure 2D). Similar effects were observed
when studying the effect of GA on the sequestration of platelets on ECs (Figure 2E). Thus,
P-selectin is a likely downstream mediator of Gas6 in promoting the sequestration of
leukocytes and platelets on activated ECs.
To further underscore that Gas6 indeed induced the surface expression of P-
selectin, we analyzed whether Gas6 affected the secretion of other factors, known to be
co-released with P-selectin. The hemostatic protein von Willebrand Factor (VWF) is such a
molecule, stored together with P-selectin in endothelial Weibel-Palade bodies and co-
released from these stores upon EC activation 38,47,48. Videomicroscopy revealed that EC
activation by A23187 in WT mice exposed VWF on the luminal surface of ECs, visualized
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as ‘platelet strings’ sequestered onto VWF multimers 39. In contrast, in Gas6-/- mice, fewer
platelet strings were detected and only at later time points (Figure 2F). The reduced VWF-
platelet strings in Gas6-/- mice were not attributable to an impaired capacity of Gas6-/-
platelets to bind VWF (not shown), or to a reduced number of Weibel-Palade bodies in
Gas6-/- ECs (total volume of Weibel-Palade bodies per image stack in computed voxels:
27,400 ± 7,030 in WT ECs versus 32,100 ± 8,250 in Gas6-/- ECs; N=8; P=NS; Figure S1).
Together, these findings suggest that, in the absence of Gas6, endothelial degranulation
upon EC activation with A23187 is impaired.
GAS6 PROMOTES THE SEQUESTRATION OF PLATELET-LEUKOCYTE-CONJUGATES
Recent reports indicate that platelets play a pivotal role in the sequestration of
leukocytes on ECs in a P-selectin-dependent manner 11,45. Indeed, through P-selectin,
platelets bind to the P-selectin ligand PSGL on leukocytes, and thereby form multicellular
conjugates, which allows them to release cytokines to further activate the leukocytes 11,49.
These conjugates of P-selectin+ platelets / PSGL+ leukocytes tether and roll on ECs, with a
higher avidity than unconjugated leukocytes, thereby enhancing endothelial inflammation
42,44. In addition, the P-selectin mediated leukocyte activation, which results from leukocyte
conjugation with platelets, further promotes leukocyte sequestration to the endothelium
and subsequent extravasation, overall leading to an amplified inflammatory response
41,43,46. We previously showed that P-selectin levels on activated platelets were reduced in
the absence of Gas6 7. Here, we analyzed, by flow cytometry, the formation of
heteroconjugates, consisting of CD41/61+ platelets and CD45+ granulocytes in WT and
Gas6-/- mice. Comparable amounts of conjugates were present in baseline conditions in
both genotypes (% of total number of granulocytes: 1.2 ± 0.2% in Gas6-/- mice versus 1.3
± 0.4% in WT mice; N=5; P=NS). However, after administration of LPS (40 mg/kg i.p.),
fewer conjugates formed in Gas6-/- than WT animals (3.0 ± 0.4% in Gas6-/- mice versus 4.7
± 0.6% in WT mice; N=5; P<0.05). A similar 4-fold increase in heteroconjugate formation
was recently shown to substantially activate circulating monocytes 46.
By videomicroscopy, we also found that loss of Gas6 impaired the formation and
the tethering / rolling of these conjugates onto the endothelium. In baseline conditions, no
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genotypic differences were found in the number of conjugates visualized per min in the
mouse mesenteric circulation (3 ± 1 in WT mice versus 2 ± 1 in Gas6-/- mice; N=10-16;
P=NS), and none of them tethered / rolled. Upon selective activation of platelets (see
above), fewer conjugates were visualized in Gas6-/- mice (conjugates observed per min:
32 ± 9 in WT mice versus 5 ± 2 in Gas6-/- mice; N=10-14; P<0.05). Correspondingly,
conjugates interacted more with the endothelium in WT than Gas6-/- mice (conjugates
tethering / rolling per min: 5 ± 2 in WT mice versus 2 ± 1 in Gas6-/- mice; N=10-14;
P<0.05). After activation of both platelets and ECs, fewer conjugates formed and tethered /
rolled onto the endothelium in Gas6-/- mice (conjugates observed per min: 36 ± 6 in WT
mice versus 4 ± 1 in Gas6-/- mice; conjugates tethering / rolling per min: 17 ± 5 in WT mice
versus 1 ± 1 in Gas6-/- mice; N=12-15; P<0.05). Thus, Gas6 promotes both, the formation
and endothelial sequestration of platelet-leukocyte conjugates, likely by regulating the
expression levels of platelet and endothelial P-selectin. Overall, Gas6 participates in the
inflammatory response between ECs, platelets and leukocytes, by regulating the release
of tethering and adhesion receptors in these cells.
GAS6 PROMOTES LEUKOCYTE EXTRAVASATION DURING INFLAMMATION
The above mentioned findings suggested that Gas6 might play a role in augmenting
the inflammatory response in vivo. In order to further underscore this hypothesis
experimentally, we exposed Gas6-/- mice to a panel of inflammatory challenges in vivo,
including endotoxinemia, vasculitis and heterotopic heart transplantation. To characterize
leukocyte infiltration in inflamed tissue, we systemically injected LPS, a model of
endotoxinemia, in WT and Gas6-/- mice. As expected, within 4 hours after intraperitoneal
injection of 20 mg/kg LPS, pulmonary myeloperoxidase activity levels – a measure of
infiltrated leukocytes – increased in WT mice (absorbance units/mg tissue: 11 ± 2 after
saline versus 23 ± 3 after LPS; N=7-12; P<0.05). In contrast, in Gas6-/- mice, pulmonary
myeloperoxidase levels failed to increase at all (absorbance units/mg tissue: 8 ± 3 after
saline versus  10 ± 2 after LPS; N=5-8; P=NS), suggesting that extravasation of
inflammatory cells was impaired in Gas6-/- mice. CD45 immunostaining confirmed that
fewer CD45+ leukocytes extravasated in the lungs of Gas6-/- than WT animals (Figure
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3A,B). Thus, Gas6 is required for leukocyte extravasation in conditions of systemic
inflammation.
GAS6 PROMOTES VASCULITIS
We also injected LPS in the footpad of mice to induce localized vasculitis and
thrombosis (“Schwartzman reaction”). Injection of 50 µg of LPS (in 20 µl saline) in the
footpad caused redness, swelling and temperature elevation of the footpad in both
genotypes. However, semi-quantitative scoring of redness and swelling revealed that,
compared to WT mice, these symptoms were less severe in Gas6-/- mice. Indeed, when
scoring the redness on a scale from 0-3 (ranging from ‘no redness’ to ‘light red’ over ‘dark
red’ to ‘gangrene’), a significant genotypic difference was found after injection of 50 µg of
LPS (redness score: 2.4 ± 0.2 in WT mice versus 1.6 ± 0.2 in Gas6-/- animals; N=6;
P<0.05). Histological analysis showed that fewer leukocytes accumulated in the adventitia
of vessels in Gas6-/- mice (CD45+ cells, % of all cells per microscopic field: 68 ± 5% in WT
mice versus 10 ± 4% in Gas6-/- mice; N=6; P<0.05, Figure 3C,D), suggesting that loss of
Gas6 attenuated the severity of vasculitis. In addition, fewer leukocytes infiltrated the
inflamed muscle in Gas6-/- mice (CD45+ cells, % of all cells per microscopic field: 51 ± 12%
in WT mice versus 29 ± 15% in Gas6-/- mice; N=6; P<0.05, Figure 3C,D). Hence, loss of
Gas6 impaired leukocyte extravasation in conditions of local inflammation.
Venous thrombosis during vasculitis was also reduced in Gas6-/- mice. Indeed,
injection of 50 µg LPS caused venous thrombosis in 88% of veins in WT mice, but only in
44% of veins in Gas6-/- mice (P<0.05; Figure 3E,F). Arteries characteristically contained
fewer thrombi; injection of 50 µg LPS caused arterial thrombosis in 10% of arteries in WT
mice but in none of the arteries in Gas6-/- mice. Hence, the impaired vascular inflammation
in Gas6-/- mice was accompanied by a reduced incidence of venous thrombosis.
GAS6 ACCELERATES GRAFT DESTRUCTION OF TRANSPLANTED HEARTS
In an established mouse model of heterotopic heart transplantation 50, acute graft
destruction, as a consequence of an extended warm transplant ischemia time, is primarily
triggered by an intense inflammatory cell infiltration 51. WT or Gas6-/- mouse donor hearts
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were grafted in syngeneic WT or Gas6-/- recipients, respectively, and beating of the
transplanted hearts was followed daily in order to determine graft destruction. Upon
grafting of WT hearts into WT recipients, 10 of the 11 grafts stopped beating within 7 to 12
days due to profound inflammatory cell infiltration, and myocarditis, resulting in
cardiomyocyte necrosis (Figure 4A,C,E). VWF immunostaining in combination with a
nuclear counterstaining revealed that platelets, leukocytes and platelet / leukocyte
conjugates often adhered to the wall of the coronary vessels in the graft (Figure 4G,H).
By contrast, when Gas6-/- hearts were grafted in Gas6-/- recipients, all 9 grafts
survived for > 60 days, and appeared normal without signs of myocardial cell death,
inflammation, or platelet / leukocyte sequestration (P<0.05 versus WT in WT; Figure
4B,D,F,I). Consistent with our in vitro results (see above), immunostaining confirmed that
the expression of VCAM-1 and ICAM-1 by ECs was less prominent in Gas6-/- grafts
compared to WT grafts (Figure 4J-M). Thus, loss of Gas6 delays graft destruction by
attenuating tissue inflammation.
To study the relative importance of Gas6 production by the graft or recipient, we
performed additional genetic cross-over experiments. When Gas6-/- hearts were grafted
into WT recipients, 70% of the grafts stopped beating within 7 to 12 days (N=6; P<0.05
versus Gas6-/- in Gas6-/-), with histological signs of inflammation and myocardial cell death.
Similar results were obtained when WT hearts were grafted in Gas6-/- recipients (N=6;
P<0.05 versus Gas6-/- in Gas6-/-). These data suggest that Gas6 produced by both, the
donor heart (presumably produced by ECs) and host tissue (released by platelets or
circulating in the plasma), determine graft destruction.
Tjwa et al. Role of Gas6 in endothelial activation15
DISCUSSION
This study provides novel evidence that Gas6 promotes EC activation and
participates in the interactions between ECs, platelets and leukocytes during inflammation.
The principal findings of this study are: (i) Gas6 amplifies EC activation in response to
inflammatory stimuli; (ii) Gas6 promotes and accelerates the sequestration of circulating
platelets and leukocytes, in a P-selectin-dependent fashion; (iii) Gas6 also promotes the
formation and endothelial sequestration of circulating platelet-leukocyte conjugates; and
(iv) Gas6 promotes leukocyte extravasation, inflammation and thrombosis in mouse
models of endotoxinemia, vasculitis and heart transplantation. Thus, these findings
highlight a pivotal role for Gas6 in enhancing interactions between ECs and circulating
cells during inflammation.
Our findings indicate that Gas6 promotes EC activation in response to the
inflammatory stimuli TNFa or LPS. Indeed, in response to TNFa, loss or knockdown of
Gas6 attenuates endothelial expression of adhesion receptors and the release of pro-
inflammatory cytokines by both mouse and human ECs in vitro. Moreover, the impaired
recruitment of circulating cells onto Gas6-/- ECs in vivo was likely attributable to absent
expression of Gas6 by ECs, since leukocyte recruitment was impaired when ECs in Gas6-
/- mice were selectively activated.
The reduced activation of cultured Gas6-/- ECs translated in an impaired and
delayed sequestration of circulating cells onto activated endothelium in the absence of
Gas6 in vivo. Since loss of Gas6 reduced the recruitment of platelets, leukocytes and
platelet-leukocyte conjugates, we reasoned that the culprit might be reduced levels of P-
selectin, an endothelial receptor, involved in the sequestration of these cells 38,42,43.
Indeed, by intravital videomicroscopy and using a P-selectin inhibitor, we found that, upon
selective activation of the endothelium, Gas6 promotes and catalyzes the sequestration of
circulating leukocytes and platelets in a P-selectin-dependent manner. Interestingly, gallic
acid failed to suppress the sequestration of platelets and leukocytes on Gas6-/-
endothelium. Since ECs upregulate their cell surface levels of P-selectin through rapid
translocation of Weibel-Palade bodies, in which P-selectin and other molecules are stored
47, these findings suggest that release of P-selectin from these intracellular stores was
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impaired. Further support that loss of Gas6 impaired the exocytosis process of Weibel-
Palade bodies was provided by our findings that the functional release of VWF (another
molecule stored in Weibel-Palade bodies) was also defective in Gas6-/- mice, while the
number of endothelial Weibel-Palade bodies was normal.
Apart from regulating the levels of endothelial P-selectin, Gas6 also regulated the
expression of various other endothelial molecules. Indeed, in the absence of Gas6,
activated ECs failed to upregulate the expression of adhesion molecules (VCAM-1, ICAM-
1) and the release of cytokines involved in the recruitment of leukocytes (IL-1ß, IL-6). This
in vitro finding translated in a reduction of leukocyte extravasation in Gas6-/- mice in vivo,
in models of heart transplantation, endotoxinemia and vasculitis. Indeed, histological
analysis of the transplanted hearts revealed that loss of Gas6 prevented the development
of myocarditis and leukocyte infiltration in the grafts, consistent with previous reports on
the role of Gas6 in graft rejection 52,53. In graft myocarditis and destruction, endothelial
Gas6 plays a dominant role, as 70% of the cardiac grafts were rejected when Gas6-/-
recipient mice received WT donor hearts, and careful high magnification microscopic
analysis of the WT grafts revealed that platelets, leukocytes and platelet-leukocyte
conjugates often adhered to the wall of the coronary vessels. In addition, in the absence of
Gas6, leukocyte extravasation was reduced after local and systemic administration of LPS.
During endotoxinemia, loss of Gas6 also impaired the formation of platelet-leukocyte
conjugates, which might have contributed to the reduced leukocyte extravasation and
activation 11,34,49. Obviously, our findings do not exclude the possibility that Gas6 also
affects leukocytes directly. Previous reports indeed showed that Gas6 and its receptors
exert both positive and negative effects on leukocyte activation 14,27,28,31.
Platelet Gas6 probably also plays a role in orchestrating inflammation, because of
its role in regulating the expression of platelet P-selectin. Indeed, previous reports showed
that, in atherosclerosis and other inflammatory conditions, platelet P-selectin accelerates
the extravasation of leukocytes into the inflamed tissue via the formation of platelet-
leukocyte conjugates, thereby enabling binding of leukocytes to endothelial PSGL-1 or
other sialoglycoproteins 34,41,42,44. P-selectin, expressed by activated and sequestered
platelets, not only activates circulating leukocytes, but can also increase EC activation and
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the levels of endothelial P-selectin 45.  We found that, after systemic injection of LPS, the
formation of platelet-leukocyte conjugates was impaired in Gas6-/- mice, which extends our
previous report on reduced P-selectin levels in Gas6-/- platelets after activation 7. In
addition, loss of Gas6 impaired the endothelial sequestration of platelets, leukocytes and
their conjugates, which likely contributed to the reduction of graft myocarditis and
destruction in the heart transplantation model (in case Gas6-/- grafts were used). Thus,
Gas6 regulates platelet activation, the levels of platelet P-selectin and subsequent
interactions with leukocytes and ECs during inflammation.
An outstanding question is how Gas6 acts at the molecular level. ECs release Gas6
constitutively, but binding of Gas6 to Axl is redundant for regulating ICAM-1 expression in
baseline conditions. Upon activation by TNFa, ECs do not produce increased amounts of
Gas6, but respond to Gas6 (a process, requiring the presence of Axl), possibly suggesting
that Gas6 is only able to bind to Axl on activated ECs. An intriguing possibility is that the
altered lipid composition of the plasma membrane in such conditions would favour an
interaction of Gas6, via its gamma-carboxylated Gla-domain, to negatively charged
phospholipids on activated EC surfaces, thereby increasing the affinity of Gas6 for its
receptor 20. We can also not exclude the (hypothetical) possibility that Gas6 may, in
addition to its extracellular activity, also act via “intracrine” mechanisms, as recently
documented for VEGF 54. Obviously, future studies will be required to elucidate the precise
molecular mechanism of Gas6.
Our findings might also have some medical implications. Expression analyses in the
mouse indicate that ECs, platelets, and leukocytes produce and release Gas6, but Gas6
levels in human platelets are variable, from negligible 37 to substantial 7. We show here
that Gas6 also determines the response of human ECs to TNFa  in vitro. Interestingly,
Gas6 plasma levels are increased in endotoxinemic mice and septic patients (unpublished
and 29,30). Besides being a biomarker of disease severity 29,30, it remains to be investigated
whether the elevated plasma levels of Gas6 in response to sepsis are functionally
relevant. Since treatment with activated protein C, the only available drug for sepsis,
primarily protects the endothelium 55,56, our findings on the role of Gas6 in augmenting
platelet-EC-leukocyte interactions and their activation profiles suggest that inhibition of
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Gas6 might warrant further consideration as a novel strategy for the treatment of sepsis or
transplantation-induced organ rejection.
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FIGURE LEGENDS
Figure 1: Gas6 regulates EC activation in vitro and in vivo.
A,B, Stimulation of ECs with 100 ng/ml TNF-a revealed a role for Gas6 in the activation of
endothelial cells in vitro. TNF-a stimulates the production of VCAM-1 (A) and ICAM-1 (B)
by WT ECs but not by Gas6-/- ECs. Data represent mean ± SEM; *: P<0.05 versus
stimulated WT cells (N=9). C-J, In normal heart tissue (baseline), no (VCAM-1) or limited
(ICAM-1) expression of the adhesion molecules VCAM-1 (C,D) and ICAM-1 (G,H) can be
detected in the blood vessels of either WT or  Gas6-/- mice. At 24 hours after
intraperitoneal injection of a sublethal dose of TNF-a, upregulated expression of VCAM-1
(E) and ICAM-1 (I) can be seen in the endothelial cells in WT hearts, but is absent (VCAM-
1) or reduced (ICAM-1) in Gas6-/- hearts (F,J). Magnification bar: 50 µm in all panels. K,
Knock-down of Gas6 or Axl in HUVECs by transfection of cells with 25 nM siRNA for
respectively, Gas6 or Axl, reduced the expression of hICAM-1 in response to TNF-a (10
ng/ml). In contrast, knock-down of Tyro3, using 100 nM of Tyro3 siRNA, failed to reduce
the expression of hICAM-1 on HUVECs in response to TNF-a (10 ng/ml). Data represent
% of the control response; P<0.05 versus control siRNA (N=3).
Figure 2: Gas6 promotes endothelial sequestration of platelets and leukocytes via
P-selectin.
A,B, In vivo videomicroscopy of mesenteric venules revealed impaired platelet-EC
interactions in Gas6-/- mice. Compared to WT mice, fewer platelets tethered/rolled (A) and
adhered (B) onto the endothelial surface of the venules after single or combined activation
of ECs and platelets. The endothelium was selectively activated by topical administration
of A23187. Platelets were selectively activated by injection of collagen together with a
GPIIb/IIIa antagonist to avoid aggregation.  *: P<0.05 versus WT (N=10-21). C, Loss of
Gas6 delayed and impaired the sequestration of leukocytes onto the endothelium,
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activated by topical administration of A23187. P<0.05 versus WT (ANOVA). *: P<0.05
versus WT per time point (N=10-16). D,E, Impaired and delayed sequestration of
leukocytes (D) and platelets (E) onto activated endothelium in Gas6-/- mice can be
explained by reduced P-selectin expression as P-selectin inhibition, by systemic infusion of
gallic acid (GA), effectively reduced the interactions between circulating cells and the
activated endothelium in WT mice but not in Gas6-/- mice. Data were expressed as % of
the maximal value in WT mice. P<0.05 versus WT (ANOVA; N=7-16 for leukocytes; N=7-
10 for platelets). F, Release of vWF strings was impaired and delayed in Gas6-/- mice after
topical administration of A23187. Data were expressed as % of positive vessels per time
point. P<0.05 versus WT (ANOVA; N=10-16).
Figure 3: In vivo role of Gas6 in inflammation and thrombosis.
A,B, CD45 staining in lungs of Gas6+/+ and Gas6-/- mice 4 hours after i.p. injection of 20
mg/kg LPS, showed higher neutrophil extravasation in the lung parenchyme of Gas6+/+
mice (A) compared to Gas6-/- animals (B). C,D, CD45 immunostaining in footpads of
Gas6+/+ and Gas6-/- animals, injected with 50 µg LPS, revealed extensive inflammation in
the adventitial and muscle area of Gas6+/+ animals (E), while vessels in Gas6-/- animals
were less inflamed (D). E,F, H&E staining in footpads of WT and Gas6-/- animals, injected
with 50 mg LPS, revealed the presence of large, organized thrombi covering most of the
lumen in veins of Gas6+/+ animals (E), while vessels in Gas6-/- animals contained fewer
and smaller thrombi (F). Magnification bar: 50 µm in all panels.
Figure 4: Role of Gas6 in graft destruction of mouse heart grafts exposed to warm
ischemia.
A-F, H&E (A,D) and CD45  (E,F) stainings of sections through WT and Gas6-/- mouse
heart grafts, 10 days after transplantation, revealed profound inflammatory cell infiltration
and myocardial cell necrosis (A,C,E) in the WT heart graft. In contrast, the Gas6-/-
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transplanted heart graft showed a remarkably normal morphology and only limited
leukocyte infiltration (B,D,F). G-I, Immunostaining for VWF (brown) combined with nuclear
counterstaining with Harris hematoxylin (blue) revealed platelets (arrowhead in H),
leukocytes and platelet-leukocyte conjugates (arrowhead in G) adhering to the wall of the
coronary vessels in the graft of WT mice while this was not seen in hearts transplanted in
Gas6-/- mice (I). J-M, VCAM-1 (J,K) and ICAM-1 (L,M) upregulated expression is reduced
in Gas6-/- hearts transplanted into Gas6-/- mice (K,M) as compared to Gas6+/+ cardiac
grafts, dissected 3 days after transplantation into Gas6+/+ mice (J,L). Magnification bar:
100 µm in panels A,B; 50 µm in panels C-F and J-M and 10 µm in panels G-I.
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Supplement Figure S1:A,B, Immunolabeling of aortic whole mounts for von Willebrand
factor (VWF) revealed an identical labeling of VWF-positive Weibel-Palade bodies in the
ECs of WT and Gas6-/- aorta. Scale bar: 20 µm in panels A,B.
SUPPLEMENTAL METHODS
Determination of Weibel-Palade body content
To determine the amount of Weibel-Palade bodies in WT and Gas6-/- ECs, we perfused
WT and Gas6-/- mice with 4% phosphate buffered paraformaldehyde. The aorta was
dissected and opened via a longitudinal ventral incision, flat mounted for 1h in the same
fixative, rinsed and processed as whole mount in an immunofluorescent staining for von
Willebrand factor (VWF). Immunostained aorta pieces were analyzed using confocal
microscopy. The 3D reconstruction of the confocal image stacks and volume calculation of
VWF-stained granules (Weibel-Palade bodies) were accomplished by using IMARIS V.5.5
software (Bitplane). Image stacks of WT and Gas6-/- aortas contained on average a similar
number of ECs (data not shown).
FACS analysis
Flow cytometric analysis of platelet-leukocyte conjugates were performed as described
previously 1,2 In brief, peripheral blood was repetitively sampled via the retro-orbital plexus
from LPS-treated mice (20 or 40 µg/g) and anti-coagulated via 4% sodium citrate, hirudin
(200 µg/ml) and G4120 (10 µg/ml). After fixation and red blood cell lysis, cells were
double-labeled with FITC-labeled anti-aIIbb3 (CD41/61, Emfret) in combination with PE-
labeled anti-CD45 (BD Biosciences). Because of more reliable gating of granulocytes than
of monocytes in murine blood, CD41/61+CD45+ platelet-granulocyte conjugates were
enumerated. 
Animal models
Administration of endotoxin: For systemic injection, endotoxin (E. coli lipopolysaccharide,
serotype 0111:B4 from Sigma) was injected i.p. in 10-12 week old mice (20 µg of LPS per
g of body weight). After 4 h, lungs were dissected, fixed, embedded in paraffin, sectioned
and stained with H&E or immunolabeled with antibodies to CD45 (rat monoclonal, 1:20,
BD Biosciences). Myeloperoxidase (MPO) activity was assayed using a modification of a
previously described protocol 3. Briefly, part of the left lung was removed, weighed and
homogenized in 1.5 ml of phosphate buffer and centrifuged (20000 x g, 20 min). Lung
precipitates were resuspended in 0.5 ml of phosphate buffer with 14 mM hexadecil trimetil
ammonium bromide, sonicated and exposed to 3 freeze-thaw cycles, incubated for 2 hours
at 60ºC and centrifuged (15000 x g, 15 min). Twenty µl of supernatants were incubated for
15 min with substrate buffer (150 µl of phosphate buffer supplemented with 5 mM EDTA),
tetramethyl-benzidine (10 µl of 5 mg/ml in DMSO) and H2O2 (10 µl of a 0.5% solution) and
absorbance (460 nm) was measured. For the local Schwartzman reaction, endotoxin (20
µl of 2.5 mg/ml) was injected into the right footpad of both WT and Gas6-/- mice as
described 4. Saline was injected into the left footpad as a control. After 5 days, mice were
sacrificed and both right and left footpads were excised, fixed in 1% paraformaldehyde
overnight and embedded in paraffin. Seven µm sections were stained with H&E and CD45
(see above). Vessels were scored for the presence of thrombi and the number of CD45+
cells per area was calculated (counted in 20 standard fields at a magnification of 630x).
Heart transplantation model: Mouse hearts (of 100% C57BL/6 WT or Gas6-/- mice) were
heterotopically transplanted as primary vascularized grafts in the neck of syngeneic WT or
Gas6-/- recipient mice as previously described 5. Briefly, hearts were harvested from
donors euthanized by CO2 asphyxiation. For induction of warm ischemia injury, donor
hearts were left in situ at room temperature for 45 min before prelevation from the donor
animals. Our previous experiments showed that warm ischemia injury caused remarkable
pathological injury, but did not interfere with initial graft beating immediately after
establishing the blood circulation. Mouse donor hearts were subsequently transplanted
heterotopically in the cervical region of recipient mice. The recipients were anesthetized by
Enflurane (Abbott), supplemented with oxygen through a semiclosed circuit inhalation
system. The aorta and pulmonary artery of the donor were anastomosed to the carotid
artery and jugular vein of the recipient by microsuture techniques. Spontaneous contractile
activity was initiated by reperfusion of the graft. Cardiac grafts were functionally assessed
by daily palpation, and graft destruction, as a consequence of an extended warm
transplant ischemia time, was diagnosed by cessation of spontaneous contractile activity.
Mouse cardiac grafts were removed for histological analysis at 3, 10 or 30 days after
transplantation or immediately after cessation of graft beating, cryo-embedded or fixed in
1% phosphate buffered paraformaldehyde overnight and embedded in paraffin. Seven µm
paraffin sections were used for analysis of general heart morphology after H&E staining or
immunostaining for CD45 (see above), or VWF (rabbit polyclonal, 1:500, Dakocytomation).
Seven µm cryo-sections were briefly fixed in aceton and immunostained with a biotinylated
rat anti-VCAM-1 (1:50, BD Biosciences) and a rat anti-ICAM-1 (CD54, 1:100, Seikagaku)
as described above.
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